Physician profile
Kenneth I Oriordan
NPI 1912075649
$7,171.81
in general payments reported to CMS, 2019-2025
31 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,098 · 2020: $595 · 2021: $1,460 · 2022: $1,670 · 2023: $1,228 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,641.15 | 2019-2023 | |
| Abbvie INC. | $1,515.53 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $722.73 | 2019-2023 | Gattex, Entyvio |
| Janssen Biotech, INC. | $646.21 | 2019-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $463.12 | 2019-2023 | Xifaxan, Trulance |
| Celgene Corporation | $145.67 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $124.73 | 2019-2022 | |
| Braintree Laboratories, INC. | $108.80 | 2021-2023 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $106.56 | 2020-2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $80.06 | 2019-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $64.49 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $63.04 | 2022 | |
| Redhill Biopharma INC. | $57.55 | 2020-2022 | |
| Genzyme Corporation | $53.13 | 2023 | |
| Merck Sharp & Dohme LLC | $45.08 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $41.13 | 2019-2020 | |
| Pfizer INC. | $40.61 | 2021-2023 | |
| Allergan, INC. | $31.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.88 | 2022 | |
| Boston Scientific Corporation | $21.60 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.38 | 2019 | |
| Daiichi Sankyo INC. | $18.88 | 2019 | |
| Biocon Biologics INC | $18.57 | 2023 | Hulio |
| Shionogi INC | $18.21 | 2020 | |
| Ferring Pharmaceuticals INC. | $16.42 | 2020 | |
| Vivus LLC | $15.77 | 2023 | Qsymia |
| Cumberland Pharmaceuticals, INC. | $14.65 | 2021 | |
| Romark Laboratories, Lc | $14.19 | 2019 | |
| W. L. Gore & Associates, INC. | $13.16 | 2023 | Gore Cardioform Septal Occluder |
| Alfasigma USA, INC. | $13.01 | 2020 | |
| Evoke Pharma, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Oriordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.